Posts by Abi
Rabies mRNA Vaccine
Rabies mRNA Vaccine Download the case study as a pdf: Contact Us
Read MorePoster mRNA Health Conference
Ntensify mini, for Drug Discovery and Pre-Clinical Phase.
Read MoreFact Sheet Ntensify mini
Ntensify mini, for Drug Discovery and Pre-Clinical Phase.
Read MoreFact Sheet Ntensify midi
Ntensify midi, for Clinical Phases & Commercial Production
Read MoreNew agreement paves way for development of first African-owned COVID-19 vaccine
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreUnivercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
Press Release Univercells acquires Synhelix, entering into synthetic biology and the race to next-generation DNA synthesis January 13, 2022 Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable and automated DNA synthesis technology resulting in one-step generation of long DNA fragments, at…
Read MoreQuantoom Biosciences granted $13.9 Million (€12.4 million), to support the development of its novel mRNA manufacturing platform for vaccines and therapeutics
Press Release Quantoom Biosciences granted $13.9 million (€12.4 million), to support the development of its novel MRNA manufacturing platform for vaccines and therapeutics December 20, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large-scale decentralized RNA production economically viable. Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to…
Read MoreeTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System
Press Release Etherna Immunotherapies and Quantoom Biosciences announce a strategic collaboration for the development of a novel RNA production system June 29, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large scale decentralized RNA production economically viable. eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies with in-house…
Read More